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Available online xxxxBackground: Coronary artery calcium (CAC) scanning has evolved into an important subclinical prediction
method for cardiovascular diseases in asymptomatic subjects. However, the prognostic implication of CAC scan-
ning in symptomatic individuals is less clear.
Objectives: To assess the prognostic utility of CAC in predicting risk of major adverse cardiac events (MACE) in
stable patients with suspected CAD.
Methods:We did a systematic electronic literature search for studies presenting original data in CAC score, and
reporting cardiovascular events in stable, symptomatic patients as primary outcome. Primary outcome of the
meta-analysiswas the occurrence ofMACE, a composite of late coronary revascularization, hospitalization for un-
stable angina or heart failure, nonfatal myocardial infarction, and cardiac death or all-causemortality. Using ran-
dom effects models, we pooled relative risk ratios of CAC for MACE, and adjusted hazard ratios (HR) of the
associations between different CAC strata (CAC 0–100,100–400, and ≥ 400, versus CAC= 0) and incident MACE.
Results:We included 19 observational studies (n=34,041). In total, 1601 events were analyzed, of which 158 in
patients with CAC= 0. The pooled relative risk ratio was 5.71 (95%-CI: 3.98;8.19) for subjects with CAC N 0. The
pooled estimate of adjusted HRs demonstrated increasing, positive associations, with the strongest association
for CAC N 400 (HR: 4.88; 95%-CI: 2.44;9.27).
Conclusions: This meta-analysis demonstrated that increased levels of CAC are strongly and independently asso-
ciatedwith increased risk forMACE in stable, symptomatic patients with suspected CAD, showing increasing risk
with greater CAC scores. Application of CAC scanning as a prediction method could be useful for a considerable
number of such patients.






During the past two decades, coronary artery calcium (CAC) scan-
ning has evolved into an important prediction method for cardiovascu-
lar diseases (CVD) [1,2]. In combination with traditional risk factors,
CAC can be used to calculate an accurate estimate of the 10-year coro-
nary heart disease risk in men and women without symptoms [3]. For
these reasons, the 2013 ACCF/AHA Risk Assessment Guidelines has
given CAC scanning Class IIa and IIb recommendations for theability and freedom from bias of
rdiology, Erasmus MC, P.O. Box
s).
ioe, D. Rijlaarsdam-Hermsen,
alysis of 34,..., International Jevaluation of CVD risk in intermediate and low-to-intermediate asymp-
tomatic subjects, respectively [4,5].
While CAC testing is mainly done in asymptomatic individuals, sev-
eral studies have evaluated the prognostic value of CAC in symptomatic
patients. However, the implication of CAC testing in such subjects is less
clear, as a result of heterogeneity of the patient groups studied. Some
studies included (solely) patients referred for diagnostic evaluation in
suspected CAD, while others investigated patients self-referred to an
emergency department for acute symptoms, or a combination of both.
Of note, the majority of meta-analyses published to date have included
either asymptomatic patients or patients in different clinical settings,
and thus provide data that cannot be extrapolated easily to stable symp-
tomatic patients [6–9]. Hence, the aim of this paper was to provide a
comprehensive overview of the existing literature on the prognostic
value of CAC in a large group of patients with stable symptoms.R.T. van Domburg, et al., Prognostic value of coronary artery calcium
ournal of Cardiology, https://doi.org/10.1016/j.ijcard.2019.06.003
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on the prognostic utility of CAC in predicting risk of major adverse car-
diac events (MACE) in stable patients presenting with suspected coro-
nary artery disease (CAD). This paper thus describes risk ratios for a
composite outcome of MACE for patients with positive CAC scores rela-
tive to subjects without CAC.
2. Methods
2.1. Data sources and search strategy
Weconducted ameta-analysis using theMeta-analysis of Observational Studies in Ep-
idemiology (MOOSE) guidelines [10]. Together with an experienced librarian (W.B.), we
searched EMBASE, OvidMEDLINE,Web of Science, Cochrane CENTRAL andGoogle Scholar
until September 2017. A complete overview of the search terms can be found in the online
data supplement. No restrictions on language or date were applied. In case of potentially
eligible articles with a different alphabet assistance was sought from native speakers or
digital translation resources. Additionally, we screened the bibliographies of key articles
for potentially eligible records.
2.2. Study selection
We included studies that presented original data on CAC score, and that reported car-
diovascular events as primary outcome. All studies had to provide either absolute num-
bers of events in patient groups according to their CAC status or cox proportional hazard
ratios (HRs) for the prediction of events. In addition, the patient population should com-
prise stable symptomatic patients with a suspicion of CAD in at least 50% of the population
studied. We excluded studies in which ≥5% of the population had a known history of CAD
at baseline. In addition, we excluded studies including symptomatic patients examined in
an emergency care setting.
2.3. Data extraction and quality assessment
Two independent investigators (M.S.L. and J.W.D.) examined the titles and abstracts
of the reports retrieved through the database search. Reports that appeared to meet the
inclusion criteriawere assessed in detail by reviewing the full-texts.We contacted authors
by email if they did not report absolute numbers of events per CAC status. We extracted
data on study design, clinical characteristics of participants, follow-up duration, sample
size, number of events according to patients' CAC status, pre-test likelihood of CAD, CT
scanner, and timing of patient enrollment. In studies reporting multiple cardiac events
per patient, only one event was counted as MACE.
The quality of the included studies was assessed using Hayden's quality appraisal for
prognostic studies [11]. Domains of potential biases that were relevant for our meta-
analysis included [1] study participation, [2] prognostic factor measurement, and [3] out-
come measurement. We examined these domains using the corresponding guidelines.
2.4. Endpoints
The outcome of our meta-analysis was the occurrence of MACE, defined as the com-
posite incidence of any of the following: late cardiac revascularization (coronary artery by-
pass graft or percutaneous coronary intervention), hospitalization for unstable angina
pectoris or heart failure, nonfatal myocardial infarction, and cardiac death or all-cause
mortality. Furthermore, we investigated the relationship between the presence of CAC
and the composite of nonfatal myocardial infarction and all-cause mortality.
2.5. Statistical analysis
In studies that reported the events per CAC stratum, we calculated the Mantel-
Haenszel individual and summary relative risk ratios and 95% confidence intervals, com-
paring the relative risks for different CAC score reference groups (CAC = 0, CAC b 100,
and CAC b 400). We used the event data in patients with CAC N 0 versus CAC = 0 to cal-
culate relative risk ratios of CAC presence.
For each study, the annual event rate per 100 patients with was CAC= 0was approx-
imated by dividing the proportion of CAC=0 patients with an event by the follow-up du-
ration in months and multiplying this by 12.
Furthermore, we pooled adjustedHRs of the associations between different CAC strata
(CAC 0–100 vs CAC = 0, CAC 100–400 vs CAC = 0, and CAC ≥ 400 vs CAC = 0) and inci-
dent MACE.
Meta-analyses were done using both random and fixed effects modelling. Results are
presented in Forest plot illustrations and summarized in tables. We evaluated presence of
heterogeneity by calculating Cochran's Q statistic and the tau-squared, and quantified the
heterogeneity using the I2 index. We visually examined funnel plot symmetry to assess
publication bias. In the absence of publication bias a funnel plot should approximately re-
semble a symmetrical inverted funnel. In the presence of pronounced asymmetry, publi-
cation bias may be present. All statistical analyses were done using Rstudio software
(Version 1.0.153, Meta, Metafor, Metagen).Please cite this article as: M.S. Lo-Kioeng-Shioe, D. Rijlaarsdam-Hermsen,
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3.1. Study population
We identified 5281 reports through electronic database searches
and 4 additional reports through manual searching of bibliographies
of key articles (Fig. S1). We excluded 2928 reports on the basis of
title and 2256 on the basis of abstract. There were no eligible manu-
scripts with a different alphabet. This yielded 101 potentially rele-
vant reports of which we retrieved full-texts. After detailed
assessment of these manuscripts, 17 of 101 reports were found to
be eligible for our systematic review. Email correspondence with au-
thors of publications that did not report absolute numbers of events
per CAC status led to inclusion of two additional reports [12,13]. Our
subsequent total of 19 reports provided information on 34,041 par-
ticipants. Four of the 19 reports were multicenter studies. All studies
were observational and were published between 1996 and 2016,
with a follow-up duration that varied from 17 to 82months. The pro-
portion of women included ranged from 19% to 68%. Between 30%
and 74% of participants presented with hypertension at baseline, be-
tween 7% and 55%with diabetes. In 17 out of 19 reports patients with
a known history of CAD were excluded [12,14–28]. Among the 12
studies reporting on family history of CAD, its prevalence ranged
from 27% to 66%. The number of participants with a CAC score of
zero varied between 11% and 63%. Among the four studies reporting
lipid-lowering therapy, its prevalence ranged from 15.8% to 63%
[16,19,23,25]. Eight out of 19 studies specified type of chest pain
(i.e. typical angina, atypical angina or nonanginal chest pain)
[12,14,16,18,20,21,23,27]. The annual event rate per 100 patients
with CAC = 0 varied between 0 and 3.64 (Table 1). In addition to
CAC presence, 11 studies assessed the extent of coronary lumen ste-
nosis by coronary computed tomography angiography (CCTA). The
proportion of participants with obstructive CAD (defined as N50%
lumen stenosis) varied between 14% and 72% (Table 2).3.2. Cardiovascular events
In total, 1601 (4.7%) cardiovascular events were analyzed, 158
(1.18%) of these events occurred in patients with a CAC score of zero.
Four studies reported multiple events per study participant, for these
studies we used the number of patients in whom an event occurred
[14,18,25,26]. Eighteen [12–21,23–30] of 19 studies assessed the occur-
rence of cardiovascular events stratified per CAC status (CAC N 0 vs CAC
=0). Only one study reportedHRs per CAC stratum [22]. The pooled rel-
ative risk ratio for MACE in patients with any detectable CAC was 5.71
(95% confidence interval [CI]: 3.98 to 8.19, I2:65%) using random effects
models (Table 3, Fig. 1a). Thirteen studies presented data on the occur-
rence of either all-cause mortality or nonfatal MI, or a combination per
CAC status in addition to overall events. The pooled analysis for inci-
dence of all-causemortality or nonfatalmyocardial infarction gave a rel-
ative risk ratio of 3.64 (95% CI: 2.68 to 4.96, I2: 16%) (Fig. 1b). Themeta-
analyses comparing different CAC score reference groups are shown in
Table 3. Using a reference group of CAC = 0, both a threshold of CAC
≥ 100 and ≥ 400 yielded an increased cumulative relative risk for MACE.
Pooled estimates of HRs adjusted for clinical risk factors demon-
strated increasing and positive associations for increasing CAC strata
and risk of future events, the strongest association being found in pa-
tients with CAC N 400 (HR 4.88, 95% CI: 2.44 to 9.76, I2: 69.8%) (Online
data supplement: Table S1).
A sensitivity analysis was done for the twelve studies
[12,14–19,24,26–29] in which 100% of the patients were reported
to be symptomatic. Among these 20,421 patients, the pooled rela-
tive risk ratio for incident MACE was 5.85 (95% CI: 3.69 to 9.27, I2:
54%).R.T. van Domburg, et al., Prognostic value of coronary artery calcium
ournal of Cardiology, https://doi.org/10.1016/j.ijcard.2019.06.003
Table 1
Characteristics of included studies.






























Single-center 924 35 (mean) NR Cardiac death, MI 0 78 8% 0 MDCT/3
mm
Bom, 2016 [16] Single-center 1551 21
(median)









Single-center 424 31 (mean) 47 (10%) Cardiac death, nonfatal MI, unstable angina requiring
hospitalization, late revascularization















96 (4.1%) Cardiac death, nonfatal MI, unstable angina requiring
hospitalization, late revascularization
2 47 2% 0.10 MDCT (16,
64)













Single-center 288 82 (mean) 29 (9.1%) Cardiac death, nonfatal MI 1 22 8% 0.46 EBCT
Kunita, 2014
[21]





Single-center 3979 27 (mean) 6 (0.1%) Cardiac death, nonfatal myocardial infarction,
unstable angina requiring hospitalization, late
revascularization
NR 105 3% – MDCT
(64)/3 mm
Lee, 2016 [23] Multicenter 1077 23
(median)
36 (3.2%) Cardiac death, nonfatal MI, unstable angina, late
revascularization
6 71 7% 0.93 MDCT
(64)/3 mm
Liu, 2013 [24] Single-center 98 60 (mean) 2 (2%) Cardiac death, unstable angina requiring
revascularization
2 56 57% 2.67 MDCT
(64)/3 mm
Naya, 2013 [25] Single-center 901 18
(median)
71 (7.9%) Cardiac death, MI, heart failure requiring
rehospitalization, late revascularization













Single-center 255 38 (mean) 45 (15%) Cardiac death, MI, revascularization 1 40 16% 0.51 EBCT/3
mm
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Fig. S2 shows the funnel plot of the studies included in our meta-
analysis andmight indicate slight asymmetry and subsequent reporting
bias with smaller studies showing greater treatment effects.3.4. Quality
We assessed the quality of the included publications on three dif-
ferent domains. In total, we assessed thirteen quality items from the
following domains of potential bias: [1] study participation [2], prog-
nostic factor measurement, and [3] outcomemeasurement. On seven
of the thirteen quality items, all 19 reports reached a maximum
score. All reports provided an adequate description of the population
of interest, and all provided a clear description the prognostic factor,
i.e. the CAC score. However, five reports did not fully provide a clear
definition of the outcome of interest (Online data supplement:
Table S2).Please cite this article as: M.S. Lo-Kioeng-Shioe, D. Rijlaarsdam-Hermsen,
score in symptomatic individuals: A meta-analysis of 34,..., International J4. Discussion
Our extensive systematic literature search and analysis showed
that in symptomatic patients with suspected coronary artery dis-
ease, presence of CAC significantly predicted MACE as well as the
composite outcome of all-cause mortality and nonfatal myocardial
infarction. Importantly, these results were not modified by adjust-
ment for clinical risk factors including age, male gender, hyperten-
sion, diabetes, dyslipidemia, and current smoking. The absence of
CAC was associated with a low risk of future events. In addition to
the overall presence of CAC, we compared the risk of MACE at differ-
ent calcium score thresholds. Compared to a reference group with a
CAC score of zero, patients with scores above higher thresholds of
CAC (CAC ≥ 100 and ≥ 400) were at greatest risk for future events.
Strata with higher CAC scores were positively and significantly asso-
ciated with greater risk of incident MACE, also after adjusting for
clinical risk factors. All in all, CAC testing proved to be of significant
prognostic value for risk stratification in this symptomatic popula-
tion with suspected CAD.R.T. van Domburg, et al., Prognostic value of coronary artery calcium
































Al-Mallah, 2014 [14] 57 50% 27.5 50% 13% 56% 17%b 30% unk 56% 8% 49% 42% 9% Diamond &
Forrester
Becker, 2005 [15] 59 52% NR 55% 25% 44%
(HLP)
35% 66% unk 20% NR NR
Bom, 2016 [16] 58 62% 26.6 30% 8% 25%
(HLP)




58 47% NR 47% 14% 31% 21% NR 15% 44% 15% NR
Dedic, 2011 [18] 56 49% 26.8 51% 14% 59% 28% 45% 32% 36% 15% NR
Detrano, 1996 [29] 55 43% NR NR NR NR NR NR 43% 20% NR NR
Engbers, 2016 [19] 61 57% 27.6 61% 13% 43%
(HCL)




60a 33% 25.7 59% 8% 52%
(HLP)
35% 32% 29% 37% 12% 20% 74% 7% Morise
Hou, 2012 [20] 60 38% 24.1 57% 15% 27% 31% 35% 20% 63% 8% NR
Hulten, 2014 [12] 55 37% NR 52% 16% 55%
(HLP)
15%b 61% 25% 42% NR Morise, mean: 47
Keelan, 2001 [30] 56 23% NR 45% 13% NR 62%c 51% NR 11% NR NR
Kunita, 2014 [21] 65 39% 23.7 58% 33% 45%
(HCL)
31% NR unk 36% 12% NR
Kwon, 2011 [22] 60 47% 24.6 50% 16% 38% 12%b NR 15% 61% 5% 29% 65% 6% ACC/AHA
Lee, 2016 [23] 62 37% 25 42% 55% 45% 39% NR 46% 31% 17% 32% 45% 23% Framingham Risk
Score
Liu, 2013 [24] 63 19% NR 61% 22% 27%
(HCL)
14% NR 72% 15% 44% NR
Naya, 2013 [25] 61a 68% 30.2 74% 31% 54% 11% 27% unk 44% 15% NR 51% NR Duke Clinical
Score
Parma, 2016 [26] 61 64% 28.2 76% 15% 57%
(HCL)
21%c 61% unk 40% 12% NR
Schenker, 2008 [27] 61 60% 32.4 74% 28% 54%
(HLP)
14% 37% unk 34% 25% 100% NR (mean: 59.4%)
Schmermund, 2004
[28]
58 29% NR 41% 7% 57%
(HCL)
19%b NR 37% 24% NR NR
Abbreviations: CAD FAM= family history of CAD; DLP = dyslipidemia; HCL = hypercholesterolemia; HLP = hyperlipidemia; HTN = hypertension; Interm. = intermediate; NR = not
reported; P (D+) = pre-test likelihood; unk = unknown.
a Median age.
b Current smoking.
c Any history of smoking.
4 M.S. Lo-Kioeng-Shioe et al. / International Journal of Cardiology xxx (xxxx) xxxOurs is not the first meta-analysis of CAC scanning in symptom-
atic subjects. In 2009, Sarwar et al. described the prognostic value
of CAC absence in symptomatic patients [31]. Based on their pooled
analysis of 7 studies including almost 4000 patients, the cumulative
relative risk ratio for patients with a CAC score of zero as compared
with patients with positive CAC scores was found to be 0.09, concor-
dant with our results. Nonetheless, our meta-analysis differs from
this previous analysis in several aspects. First, we were able toTable 3
Meta-analysis comparing risk for MACE at different thresholds of CAC.
Threshold of CAC score evaluated No of studies No of participant
CAC score = 0 as reference group:
Score N 0 vs 0 87(12–21,23–30) 30,057
Score N/100 vs 0 7(13,18-21,24,28) 9434
Score N/400 vs 0 9(13,18-21,23-25,27) 8577
CAC score b 100 as reference group:
Score N/100 vs b100 7(13,18-21,24,28) 13,198
Score N/400 vs b100 6(13,18-21,24) 10,762
CAC score b 400 as reference group:
Score N/400 vs b400 9(13,18-21,23-25,27) 15,368
Please cite this article as: M.S. Lo-Kioeng-Shioe, D. Rijlaarsdam-Hermsen,
score in symptomatic individuals: A meta-analysis of 34,..., International Jinclude 13 new studies that additionally contributed over 31,000 pa-
tients [12–14,16–23,25,26]. Second, we excluded studies on patients
presenting with acute symptoms and, third, uphold a higher thresh-
old for CAD suspicion. These actions resulted in a better defined and
more homogenous study population. Fourth, we analyzed both the
prognostic value of CAC per CAC status (CAC N 0 versus CAC = 0),
as well as per different thresholds of CAC and CAC strata. Fifth and
last, while a large number of events in the published literatures evaluated RR (95% CI) I2 t2
Random effects 5.71 [3.98;8.19] 65% 0.2778
Fixed effects 6.58 [5.58; 7.76]
Random effects 9.57 [6.87;13.33] 23% 0.0433
Fixed effects 9.71 [7.70;12.25]
Random effects 8.30 [4.95;13.90] 77% 0.4083
Fixed effects 9.21 [7.47;11.36]
Random effects 4.09 [2.85;5.89] 79% 0.1652
Fixed effects 4.81 [4.19;5.53]
Random effects 5.08 [3.52;7.34] 75% 0.1389
Fixed effects 6.03 [5.16;7.05]
Random effects 3.30 [2.41;4.51] 83% 0.1746
Fixed effects 3.83 [3.41;4.31]
R.T. van Domburg, et al., Prognostic value of coronary artery calcium
ournal of Cardiology, https://doi.org/10.1016/j.ijcard.2019.06.003
Fig. 1. Title: Relative risk ratios for MACE CAC N 0 vs CAC= 0. Legend: panel A shows the relative risk ratios for MACE in patients with CAC N 0 versus CAC= 0; panel B shows the relative
risk ratios for all-causemortality and nonfatal myocardial infarction in patients with CAC N 0 versus CAC= 0. Abbreviations: CAC= coronary artery calcium; CI= confidence interval; RR
= relative risk.
5M.S. Lo-Kioeng-Shioe et al. / International Journal of Cardiology xxx (xxxx) xxxconsists of coronary revascularizations, we analyzed the value of CAC
scanning on ‘hard endpoints’, i.e. the composite of all-cause mortal-
ity and nonfatal myocardial infarction.
Pooled results from 5 population-based cohort studies with 6739
low-risk women showed that CAC was associated with increased risk
of atherosclerotic CVD [7]. In that study, patients with positive CAC
scores had a hazard ratio of 2.04 as compared with patients without
any CAC. Another study found no significant differences between men
and women for mild- to high-risk CAC scores, suggesting an equivalent
ability to stratify CVD risk by gender [32]. The data in the studies we in-
cluded did not allowus to stratify by gender. In a recentmeta-analysis of
stable patients presentingwith acute symptoms, absence of CACwas as-
sociated with significantly lower risk of future cardiovascular events
[33]. Although these meta-analyses included different study popula-
tions, their findings are consistent with our data on symptomatic pa-
tients with stable symptoms.Please cite this article as: M.S. Lo-Kioeng-Shioe, D. Rijlaarsdam-Hermsen,
score in symptomatic individuals: A meta-analysis of 34,..., International JIn our analyses we used a CAC score threshold of N400,which is sim-
ilar to the thresholds used in the studies we included. However, the re-
cently updated SCCT expert consensus statement for CAC scoring
recommends using a threshold of CAC score N 300 [34].
The persistent interest in the predictive utility of CAC testing is not
surprising. In the asymptomatic population, CAC scoring has proven to
be a reliable method for estimating calcified plaque burden and identi-
fying future cardiovascular events. When added to existing risk predic-
tion algorithms, CAC testing was shown to reliably predict future CVD
events [35]. CAC testingwas found to be cost-effective in the assessment
of intermediate risk patients [36].
CAC testing can preclude the need for further downstream testing
[37,38], and both screening and identification of CAC abnormalities
may lead to improvements in cardiovascular risk factors [39]. In addi-
tion, there is evidence indicating that CAC testing has positive impact
on adherence of statin therapy and lifestyle changes [40,41]. Given itsR.T. van Domburg, et al., Prognostic value of coronary artery calcium
ournal of Cardiology, https://doi.org/10.1016/j.ijcard.2019.06.003
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plausible that CAC scoring will play an increasingly important role in
health care management for the asymptomatic population [42,43].
The diagnostic value of CAC scanning in symptomatic patients is in-
creasingly being investigated. Compared to CCTA, CAC testing has the
additional benefit of being rapid and non-invasive, not requiring veni-
puncture, and being easily accessible. The prognostic value of CAC com-
pared to functional stress testing among stable patients with suspected
CAD was recently investigated in a prospective trial. In that trial, most
patients who experienced clinical events presented with positive CAC
scans, while only a minority exhibited functional stress test abnormali-
ties. Still, as a result of the higher specificity of the abnormal functional
test, both tests were found to have similar discriminatory abilities [44].
As stated previously, it is plausible that CAC scoring will play an in-
creasingly important role in health care management for the asymp-
tomatic population [42,43]. Similarly, the diagnostic role of CAC
testing in symptomatic patients might gain greater clinical utility. Al-
though CCTA may be done in many symptomatic patients, pre-
angiographic CAC scoring may be helpful in the decision to proceed to
angiography or to defer the procedure. But in particular in the primary
care setting, CAC testing may prove to be very useful, since referral
may not be indicated in men and women with mild symptoms and rel-
atively low CAC scores.
As stated previously, current literature provides solid evidence that
absence of CAC is associated with favorable prognosis in asymptomatic
individuals [45,2]. The same evidence is now emerging that this holds
true in symptomatic patients as well [31,46–49]. Nonetheless, the re-
sults of different studies addressing outpatients with a CAC score of
zero appear equivocal [47,50]. For instance, Gottlieb et al. () found
that absence of CAC did not exclude the presence of obstructive stenoses
or the need for revascularization in their population with suspected
CAD and high pretest probability. Separate analyses from a symptom-
atic cohort trial showed that CAC absence did significantly reduce, but
did not fully eliminate the occurrence of obstructive CAD [47]. Still,
the absence of CAC significantly lowered the risk of adverse future
events in all reports on CAC scanning. Of course, no normal test outcome
– not even normal coronary angiography – can guarantee a completely
event-free in all patients and doctors must remain vigilant when CAD is
still suspected on clinical grounds.
In total, 13 of the CAC studies that we analyzed, reported on
subsequent coronary revascularizations, either percutaneous coro-
nary intervention or coronary artery bypass graft. Of these studies,
11 included only late, from 60 days to 6 months post coronary
CCTA, revascularizations. Exclusion of early revascularizations
from survival analysis could minimize verification bias [51]. Of
course, patients with significant coronary lumen stenosis (≥50%)
by CCTA are more likely to undergo invasive angiography and re-
vascularization early post-CCTA in clinical practice. Late revascular-
izations, on the other hand, are less frequently associated with
CCTA findings and more often triggered by the symptomatology
of patients. Three studies that we reported did not separately con-
sider early and late coronary revascularizations. When we studied
the relation between CAC scores and all-cause mortality and myo-
cardial infarction, after the exclusion of events as revasculariza-
tions and hospitalizations, we found that patients with positive
CAC scores had a 5-fold increased risk. Appropriate preventive
treatment of patients with coronary calcium should reduce their
risk of future complications.
4.1. Strengths & limitations
Our meta-analysis is not without limitations. We recognize the
importance of the specific usefulness of CAC scoring in patients
with low to intermediate CAD probability and with non-specific
or atypical chest pain. Unfortunately, since the majority of studies
did not specify type of chest pain, it was not possible to analyzePlease cite this article as: M.S. Lo-Kioeng-Shioe, D. Rijlaarsdam-Hermsen,
score in symptomatic individuals: A meta-analysis of 34,..., International Jthis separately and thus better estimate the usefulness of CAC
score in symptomatic patients. Second, assessment of the large
number of studies that were included in our analyses showed
some heterogeneity among the populations under study. This was
accounted for by applying random effects models. Although the
findings of most studies that we included were concordant, our
findings might not be generalizable to populations that were not
represented in this meta-analysis. Third, in the analysis of the rela-
tion between CAC scores and hard events we were not able to ad-
just for several important variables, such as optimal medical
treatment and achieved LDL-cholesterol and glucose goals. Hence,
our calculated increased risk of all-cause mortality and myocardial
infarction might be an overestimation. This is, on the other hand
and to the best of our knowledge, the largest meta-analysis to re-
port the on prognostic value of CAC in stable symptomatic patients.
Our data and results confirm and strengthen the strong association
between CAC and prognosis in the symptomatic patient population.
However, the strong associations between CAC and increased risk
as reported here may be modified by proper preventive measures
in patients found to be at high risk on the basis of their calcium
score.
5. Conclusion
On the basis of our analyses on over 34,000 stable, symptomatic pa-
tients with suspected CAD, we conclude that increased levels of coro-
nary artery calcium are strongly and independently associated with
increased risk for major adverse cardiac events. In these patients, the
risk for cardiac events increased with greater CAC scores. The findings
are clinically relevant for the large group of symptomatic patients and,
although a multicenter randomized trial will be needed to assess the
exact utility and incremental predictive value of calcium testing, our
analyses indicate that CAC scanning should be helpful in clinical deci-
sionmaking in a considerable number of stable patientswith chest pain.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijcard.2019.06.003.
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